Injective (INJ) is 120.8× the size of Mitosis (MITO) by market capitalisation. Over the past 1 year, INJ is ahead by 98.8 percentage points (MITO -91.2% against INJ +7.5%). Their daily returns move barely together (correlation 0.30 across 399 shared trading days). MITO has been the more volatile of the two, at 124% annualised against INJ's 100%.
MITOINJ
0.30over 399 shared trading days
Measured on daily returns rather than on prices. Two assets that both simply trend upward score near 1.0 on raw prices whether or not they move together, so returns are what answer the question people mean by correlation.
| Metric | MITO | INJ |
|---|---|---|
| Max drawdown (400d) | -95.8% | -79.5% |
| Risk-adjusted return (90d) | -0.65 | 0.46 |
| Best 30 days (past year) | +128.4% | +92.8% |
| Worst 30 days (past year) | -76.2% | -46.8% |
Relative strength over 90 days: INJ outperformed MITO by 78.3% — measured on the MITO/INJ ratio, so it holds regardless of market direction.